Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 267 entries
View as:

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Phase: N/A Priority: Normal
NCT ID: NCT02318277 Org: User:
Start: 01/05/15 End: 10/16/20 Due: 10/16/21

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT02093429 Org: User:
Start: 01/31/14 End: 09/30/14 Due: 09/30/15

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06416800 Org: User:
Start: 06/19/24 End: 01/15/25 Due: 01/15/26

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Phase: N/A Priority: Normal
NCT ID: NCT02553330 Org: User:
Start: 11/18/15 End: 10/03/17 Due: 10/03/18

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Phase: N/A Priority: Normal
NCT ID: NCT03599713 Org: User:
Start: 02/25/19 End: 06/28/24 Due: 06/28/25

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase: N/A Priority: Normal
NCT ID: NCT03920839 Org: User:
Start: 07/15/19 End: 11/04/19 Due: 11/04/20

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03721965 Org: User:
Start: 12/31/19 End: 02/17/20 Due: 02/17/21

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00550043 Org: User:
Start: 10/31/07 End: 09/30/08 Due: 09/30/09

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03059823 Org: User:
Start: 11/15/16 End: 05/22/24 Due: 05/22/25

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase: N/A Priority: Normal
NCT ID: NCT03260894 Org: User:
Start: 12/07/17 End: 06/30/25 Due: 06/30/26

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase: N/A Priority: Normal
NCT ID: NCT03358472 Org: User:
Start: 12/01/17 End: 12/19/25 Due: 12/19/26

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Phase: N/A Priority: Normal
NCT ID: NCT06627335 Org: User:
Start: 03/27/23 End: 08/15/28 Due: 08/15/29

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase: N/A Priority: Normal
NCT ID: NCT04509700 Org: User:
Start: 08/03/20 End: 09/30/27 Due: 09/30/28

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Phase: N/A Priority: Normal
NCT ID: NCT05755438 Org: User:
Start: 03/10/23 End: 08/10/25 Due: 08/10/26

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01822756 Org: User:
Start: 04/30/13 End: 08/31/16 Due: 08/31/17

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02903914 Org: User:
Start: 09/14/16 End: 08/15/22 Due: 08/15/23

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04586244 Org: User:
Start: 01/14/22 End: 01/29/24 Due: 01/29/25

A Study of INCB050465 in Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03627065 Org: User:
Start: 02/28/19 End: 01/02/20 Due: 01/02/21

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00820950 Org: User:
Start: 05/31/07 End: 04/30/09 Due: 04/30/10

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase: N/A Priority: Normal
NCT ID: NCT03342352 Org: User:
Start: 12/15/17 End: 04/20/18 Due: 04/20/19

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT03320642 Org: User:
Start: 02/27/18 End: 02/17/22 Due: 02/17/23

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01858883 Org: User:
Start: 06/30/13 End: 03/31/16 Due: 03/31/17

A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06555081 Org: User:
Start: 09/25/24 End: 11/07/24 Due: 11/07/25

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03144687 Org: User:
Start: 01/26/18 End: 06/01/21 Due: 06/01/22

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

Phase: N/A Priority: Normal
NCT ID: NCT04818346 Org: User:
Start: 05/06/21 End: 05/24/23 Due: 05/24/24